Doxycycline vs. macrolides in combination therapy for treatment of community‐acquired pneumonia

Abstract We assessed the comparative efficacy of empirical therapy with beta-lactam plus macrolide vs. beta-lactam plus doxycycline for the treatment of community-acquired pneumonia (CAP) among patients in the Australian Community-Acquired Pneumonia Study. Both regimens demonstrated similar outcomes against CAP due to either ‘atypical' ( Chlamydophila, Legionella or Mycoplasma spp.) or typical bacterial pathogens.